Healthcare

Mark Cuban lauds cash-pay option as Rx cost remedy

By Bruce Shutan

Published November 25, 2025 8:00 AM EST 5 Min Read

Key insight: Discover how cash-pay options and biosimilars can circumvent opaque PBM pricing models.
Quote: Mark Cuban says self-insured plans “get to write” contract terms to require cash purchases.
Forward look: Price-transparency tools (e.g., TrumpRx) will disrupt benefit design and deductible exposure.
Source: Bullets generated by AI with editorial review

Bruce Shutan

Contributing writer

Bruce Shutan is an Employee Benefit News contributing writer based in Portland, Oregon.

For reprint and licensing requests for this article, click here.

Healthcare Financial wellness

More From Employee Benefit News

Healthcare

What Trump’s ‘Great Healthcare Plan’ means for drug costs and price transparency

The legislation calls on Congress to lower prescription drug costs, shift subsidies directly to consumers, and enforce strict price transparency.

By Paola Peralta

Associate Editor

Employee Benefit News

August 17

Healthcare

Healthcare costs are forcing employers to reconsider their benefits strategy

Employers are under pressure to keep benefits competitive while controlling costs, driving new scrutiny of PBMs, hospital prices and GLP-1 coverage for 2027.

By Jimmy Nesbitt

Reporter

Employee Benefits News

August 17

Healthcare costs and fees concept.Hand of smart doctor used a calculator and smartphone for medical costs at modern hospital in sun light.

Benefits Think PBM playbook, part 2: Changes to the market and the value of a pharmacy benefits expert

A look at traditional PBMs and pass-through models, potential savings areas, developments and partnering with the right consultant.

June 5

Simon Leung

Benefits Think Rewriting the PBM playbook: Exposing hidden costs and empowering plan sponsors

Part one of this two-part series looks at the background, transparency solutions and how to understand PBM profitability.

June 4

Simon Leung

Benefits Think How disintermediation is being managed in Rx models

The objective is to have a clear view of baseline vs. current Rx trend, documented savings tied to interventions and a reconciliation check on guarantees and rebates.

April 29

Ryan Czado